(RTTNews) - Thursday, Bayer (BYR.L) announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for KERENDIA (finerenone) to treat adults with non-diabetic chronic kidney disease (CKD).
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.